| 151 |
22673193 | Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. | 2012 Jun 7 |
3 |
| 152 |
22901187 | Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. | 2012 |
1 |
| 153 |
22985566 | [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway]. | 2012 Sep |
3 |
| 154 |
23056046 | Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways. | 2012 |
1 |
| 155 |
23056575 | Identification of an annonaceous acetogenin mimetic, AA005, as an AMPK activator and autophagy inducer in colon cancer cells. | 2012 |
1 |
| 156 |
20686837 | Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. | 2011 Jul |
1 |
| 157 |
21050361 | The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. | 2011 Jul |
1 |
| 158 |
21358348 | Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. | 2011 May |
1 |
| 159 |
21764510 | Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. | 2011 Dec 1 |
1 |
| 160 |
19471857 | The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. | 2010 Aug |
1 |
| 161 |
19853261 | Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. | 2010 May |
1 |
| 162 |
20214883 | Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. | 2010 Apr 9 |
8 |
| 163 |
20847160 | 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. | 2010 Oct |
4 |
| 164 |
19058911 | System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. | 2009 Apr 8 |
2 |
| 165 |
19240722 | The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. | 2009 Mar 24 |
1 |
| 166 |
19484784 | Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. | 2009 Sep 1 |
2 |
| 167 |
19540648 | Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. | 2009 Sep |
4 |
| 168 |
19690197 | mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. | 2009 Sep 1 |
5 |
| 169 |
20066897 | Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro. | 2009 |
1 |
| 170 |
20196784 | AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. | 2009 Sep |
5 |
| 171 |
18058806 | Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. | 2008 Jun |
2 |
| 172 |
18585380 | Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. | 2008 Sep 4 |
4 |
| 173 |
17616691 | AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. | 2007 Jul 1 |
5 |
| 174 |
17634556 | RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. | 2007 Jul 15 |
1 |
| 175 |
16786123 | Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. | 2006 Jul |
1 |
| 176 |
16033649 | Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. | 2005 Jul 20 |
1 |